<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04359303</url>
  </required_header>
  <id_info>
    <org_study_id>P.Inv. Ozono-COVID19 Ver.1.2</org_study_id>
    <nct_id>NCT04359303</nct_id>
  </id_info>
  <brief_title>Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients</brief_title>
  <acronym>OzonoCOVID19</acronym>
  <official_title>Randomized Clinical Trial to Evaluate Efficacy and Safety of Systemic Indirect Endovenous Ozone Therapy (SIEVOT) as Adjuvant Treatment in COVID19 Non-intubated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Javier Hidalgo Tallón</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sociedad Española de Ozonoterapia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Católica San Antonio de Murcia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic medical ozone has proved to help in several viral diseases, chronic obstructive
      pulmonary disease and chronic inflammation process. The investigators are sure that its
      application to COVID-19 patients, as an adjuvant therapy, will improve the health status of
      these individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the extreme world situation caused by COVID19 pandemic, the investigators consider
      unethical not to try any treatment option with a justified rationale.

      The investigators have explained that medical ozone therapy has a clear scientific basement
      thanks to all preclinical and clinical investigation already published. It can be classified
      as chemical stressor that produces a modulation in the redox balance and immunity. Moreover,
      it is easy and safe to administer with insignificant side effects.

      The efficacy in viral diseases has been proved in publications together the modulation of
      interleukin 6 and other proinflammatory cytokines that could potentially help in COVID19
      patients. The improve of exchange of gases and microcirculation will surely contribute to
      enhance this patients' health status.

      As explained above, the investigators propose to carry out a randomized control trial to
      evaluate the safety and efficacy of systemic ozone (indirect endovenous) in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Control group with WHO recommended treatment. Treatment group with WHO recommended treatment + systemic ozone therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>With a randomization table, nurses will treat the patients in treatment groups. Each patient will be in individual rooms.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>COVID19 clinical scale</measure>
    <time_frame>through study completion, an average of 3 weeks</time_frame>
    <description>World Health Organization (WHO) recommended COVID19 clinical scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of died patients</measure>
    <time_frame>through study completion, an average of 3 weeks</time_frame>
    <description>Dead patients during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oro/nasopharynx virus</measure>
    <time_frame>through study completion, an average of 3 weeks</time_frame>
    <description>Oro/nasopharynx virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thorax imaging (0=none; 1=unilateral; 2=bilateral; 3=ground-glass opacification; 4=consolidation)</measure>
    <time_frame>through study completion, an average of 3 weeks</time_frame>
    <description>Thorax imaging according scale. Higher punctuation is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in hospital</measure>
    <time_frame>through study completion, an average of 3 weeks</time_frame>
    <description>Days in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous gas blood analysis</measure>
    <time_frame>through study completion, an average of 3 weeks</time_frame>
    <description>Venous gas blood analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Base WHO recommended treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TREATMENT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Base WHO recommended treatment + Systemic indirect endovenous ozone therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Systemic indirect endovenous ozone therapy</intervention_name>
    <description>200 mL at 40 mcg/mL of medical ozone / oxygen in 200 mL of patients blood mixed in an homologated device for the procedure.</description>
    <arm_group_label>TREATMENT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID19 virus detected in oro/nasopharynx

          -  mild ill according WHO numeric scale

          -  mild ill according Berlin criteria

          -  non intubated patients

          -  signed informed consent

        Exclusion Criteria:

          -  patients treated with systemic ozone in the last 6 months

          -  patients treated before with systemic ozone and referring any side effect

          -  glucose-6-phosphate-dehydrogenase deficit

          -  other severe concomitant disease apart from COVID19

          -  psychiatric disease specified in axis I of l Diagnostic and Statistical Manual of
             Mental Disorders, 5 edition, but major depression

          -  patients not capable of understanding the study methods and targets

          -  pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose Baeza Noci, MD, PhD</last_name>
    <phone>+34963177800</phone>
    <email>jose.baeza@uv.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francisco J Hidalgo Tallón, MD, PhD</last_name>
    <email>fjht63@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SEOT</name>
      <address>
        <city>Valencia</city>
        <zip>46013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Baeza Noci, MD, PhD</last_name>
      <phone>+34963177800</phone>
      <email>jose.baeza@uv.es</email>
    </contact>
    <contact_backup>
      <last_name>Francisco J Hidalgo Tallón, MD, PhD</last_name>
      <email>fjht63@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bocci V. Ozone: A new medical drug. Netherlands: Springer; 2011.</citation>
  </reference>
  <reference>
    <citation>Baeza J, Cabo JR, Gómez M, et al. WFOTs Review on Evidence Based Ozone Therapy. World Federation of Ozone Therapy. Brescia: WFOT; 2015.</citation>
  </reference>
  <reference>
    <citation>Bocci V, Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Front Chem. 2015 Feb 2;3:4. doi: 10.3389/fchem.2015.00004. eCollection 2015. Review.</citation>
    <PMID>25699252</PMID>
  </reference>
  <reference>
    <citation>Pecorelli A, Bocci V, Acquaviva A, Belmonte G, Gardi C, Virgili F, Ciccoli L, Valacchi G. NRF2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells. Toxicol Appl Pharmacol. 2013 Feb 15;267(1):30-40. doi: 10.1016/j.taap.2012.12.001. Epub 2012 Dec 16.</citation>
    <PMID>23253326</PMID>
  </reference>
  <reference>
    <citation>Re L, Martínez-Sánchez G, Bordicchia M, Malcangi G, Pocognoli A, Morales-Segura MA, Rothchild J, Rojas A. Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo? A preliminary result. Eur J Pharmacol. 2014 Nov 5;742:158-62. doi: 10.1016/j.ejphar.2014.08.029. Epub 2014 Sep 16.</citation>
    <PMID>25218903</PMID>
  </reference>
  <reference>
    <citation>Hernández Rosales FA, Calunga Fernández JL, Turrent Figueras J, Menéndez Cepero S, Montenegro Perdomo A. Ozone therapy effects on biomarkers and lung function in asthma. Arch Med Res. 2005 Sep-Oct;36(5):549-54.</citation>
    <PMID>16099337</PMID>
  </reference>
  <reference>
    <citation>Calunga JL, Paz Y, Menéndez S, Martínez A, Hernández A. [Rectal ozone therapy for patients with pulmonary emphysema]. Rev Med Chil. 2011 Apr;139(4):439-47. doi: /S0034-98872011000400004. Epub 2011 Aug 25. Spanish.</citation>
    <PMID>21879181</PMID>
  </reference>
  <reference>
    <citation>Borrelli E, Bocci V. Oxygen Ozone Therapy in the Treatment of Chronic Obstructive Pulmonary Disease: An Integrative Approach. Am J Clin Exp Med. 2014;2(2):9-13. DOI:10.11648/j.ajcem.20140202.11</citation>
  </reference>
  <reference>
    <citation>Vinnik IS, Salmina AB, Tepliakova OV, Drobushevskaia AI, Pozhilenkova EA, Morgun AV, Shapran MV, Kovalenko AO. [The results of combined ozone therapy using in complex treatment of soft tissues infections in patients with diabetes mellitus type II]. Khirurgiia (Mosk). 2015;(2):63-69. doi: 10.17116/hirurgia2015263-69. Russian.</citation>
    <PMID>26031822</PMID>
  </reference>
  <reference>
    <citation>Delgado-Roche L, Riera-Romo M, Mesta F, Hernández-Matos Y, Barrios JM, Martínez-Sánchez G, Al-Dalaien SM. Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. Eur J Pharmacol. 2017 Sep 15;811:148-154. doi: 10.1016/j.ejphar.2017.06.017. Epub 2017 Jun 13.</citation>
    <PMID>28623000</PMID>
  </reference>
  <reference>
    <citation>Niu T, Lv C, Yi G, Tang H, Gong C, Niu S. Therapeutic Effect of Medical Ozone on Lumbar Disc Herniation. Med Sci Monit. 2018 Apr 3;24:1962-1969.</citation>
    <PMID>29611536</PMID>
  </reference>
  <reference>
    <citation>Bocci V. Ozonization of blood for the therapy of viral diseases and immunodeficiencies. A hypothesis. Med Hypotheses. 1992 Sep;39(1):30-4.</citation>
    <PMID>1435389</PMID>
  </reference>
  <reference>
    <citation>Bocci V. Does ozone therapy normalize the cellular redox balance? Implications for therapy of human immunodeficiency virus infection and several other diseases. Med Hypotheses. 1996 Feb;46(2):150-4.</citation>
    <PMID>8692040</PMID>
  </reference>
  <reference>
    <citation>Bassi P, Sbrascini S, Mattassi R, D'Angelo F, Franchina A. [Ozone in the treatment of herpes zoster]. Riv Neurobiol. 1982 Jul-Dec;28(3-4):328-33. Italian.</citation>
    <PMID>7187109</PMID>
  </reference>
  <reference>
    <citation>Gierek-Lapińska A, Antoszewski Z, Myga B, Skowron J. [Preliminary report on using therapeutic ozone in infectious conjunctivitis and keratitis and in corneal degeneration]. Klin Oczna. 1992 May-Jun;94(5-6):137-8. Polish.</citation>
    <PMID>1453672</PMID>
  </reference>
  <reference>
    <citation>Mandzhgaladze NR, Kharebava ER, Didia TsG, Ardzhevanishvili MD, Gudzhabidze MV, Chigiashvili TsN. [Influence of intravenous ozone treatment on the level of different specificity antibodies]. Georgian Med News. 2006 Sep;(138):93-5. Russian.</citation>
    <PMID>17057311</PMID>
  </reference>
  <reference>
    <citation>Huang J, Huang J, Xiang Y, Gao L, Pan Y, Lu J. [Topical ozone therapy: An innovative solution to patients with herpes zoster]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Feb 28;43(2):168-172. doi: 10.11817/j.issn.1672-7347.2018.02.011. Chinese.</citation>
    <PMID>29559601</PMID>
  </reference>
  <reference>
    <citation>Jiao XJ, Peng X. [Clinilal study of medical ozone therapy in chronic hepatitis B of 20 patients]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008 Dec;22(6):484-5. Chinese.</citation>
    <PMID>19544653</PMID>
  </reference>
  <reference>
    <citation>Chernyshev AL, Filimonov RM, Karasev AV, Neronov VA, Maksimov VA. [Combined treatment including ozonotherapy of patients with viral hepatitis ]. Vopr Kurortol Fizioter Lech Fiz Kult. 2008 May-Jun;(3):19-22. Russian.</citation>
    <PMID>18655281</PMID>
  </reference>
  <reference>
    <citation>Neronov VA. [Experience with the use of ozone for the treatment of chronic viral hepatitis]. Vopr Kurortol Fizioter Lech Fiz Kult. 2009 Nov-Dec;(6):14-7. Russian.</citation>
    <PMID>20017375</PMID>
  </reference>
  <reference>
    <citation>Cespedes-Suarez J, Martin-Serrano Y, Carballosa-Peña MR, Dager-Carballosa DR . Response of patients with chronic Hepatitis B in one year of treatment with Major Autohemotherapy. J Ozone Ther. 2018:2(3) DOI:10.7203/jo3t.2.3.2018.11459</citation>
  </reference>
  <reference>
    <citation>Zaky S, Kamel SE, Hassan MS, Sallam NA, Shahata MA, Helal SR, Mahmoud H. Preliminary results of ozone therapy as a possible treatment for patients with chronic hepatitis C. J Altern Complement Med. 2011 Mar;17(3):259-63. doi: 10.1089/acm.2010.0016.</citation>
    <PMID>21417811</PMID>
  </reference>
  <reference>
    <citation>Mawsouf MN, Tanbouli TT, Viebahn-Hänsler R. Ozone therapy in patients with viral Hepatitis C: Ten Years' Experience. Ozone Sci Eng. 2012;34(6):451-458. DOI:10.1080/01919512.2012.720161</citation>
  </reference>
  <reference>
    <citation>Ibrahim AM, Elkot RA, Khashaba SA. Successful Treatment of Multiple Common Warts With Intralesional Ozone. Dermatol Surg. 2020 Jul;46(7):928-933. doi: 10.1097/DSS.0000000000002174.</citation>
    <PMID>31584525</PMID>
  </reference>
  <reference>
    <citation>Cespedes-Suarez J, Martin-Serrano Y, Carballosa-Peña MR, Dager-Carballosa DR. The immune response behavior in HIV-AIDS patients treated with Ozone therapy for two years. J Ozone Ther. 2019:2(3). DOI:10.7203/jo3t.2.3.2018.11458</citation>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>June 21, 2020</last_update_submitted>
  <last_update_submitted_qc>June 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Católica San Antonio de Murcia</investigator_affiliation>
    <investigator_full_name>Javier Hidalgo Tallón</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>ozone therapy</keyword>
  <keyword>COVID19</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>According to hospitals' statements and data protection agreements</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

